Banseog note · 2026-10-26
A company turning cell therapy plants into robotic clusters
Current stage · from public events · 2026-11-14
- R&D · prototype
- Pilot · first production
- Scaling production
- Operations · field rollout
- Going global · localizing
- M&A · integration
- Restructuring
Going global · localizing First overseas manufacturing subsidiary launched in Italy, with funding to expand clinical-stage robot deployments to commercial scale Also seen: Pilot · first production
- 2026-10-06 It announced a USD 75 million Series B round and announced plans to expand capabilities for the transition from existing clinical-stage deployments to commercial-scale production. Source
- 2026-05-27 It announced the launch of its first overseas subsidiary, Multiply Labs Italia in Turin, and the establishment of manufacturing, supply-chain and quality systems. Source
Roles often seen at this stage Production & supply chain · Quality, regulatory & clinical · Leadership, planning & admin
Companies at the same stage → · Same stage in other industries →
- A physical AI company in San Francisco, USA, founded in 2016 out of Y Combinator, it automates production processes for cell and gene therapies, antibodies, viral vectors and mRNA therapeutics with robotic clusters. The clusters are not an outsourced service; pharmaceutical companies own and operate them directly.
- The company said its robotic clusters cut the cost per dose by 74% compared with manual production and raise throughput by up to 100 times.
- As of its May 2026 announcement, it named AstraZeneca, Legend Biotech and Kyverna Therapeutics as pharmaceutical customers to which it supplies robotic clusters. In January 2026 it announced, together with NVIDIA, that it would bring physical AI robotics technology into advanced biomanufacturing.
Decisions within a year
- Pharmaceutical partnership in January 2026 it announced an evaluation collaboration with AstraZeneca to apply a GMP-ready robotic system to commercial-scale cell therapy production. The subject is a multi-arm cluster in which four robot arms work in parallel on industry-standard production equipment.
- Manufacturing base in May 2026 it set up a manufacturing subsidiary, Multiply Labs Italia, in Turin, Italy, and appointed Enrico Antonio Racca, formerly head of supply chain and manufacturing at Scuderia Ferrari, as its first general manager (GM). He is responsible for hiring the manufacturing team, designing the supply chain for large-scale cluster production and building a quality system suited to the regulatory environment.
- Fundraising in October 2026 it announced a USD 75 million Series B led by Dr. Patrick Soon-Shiong and NantWorks. AstraZeneca, Teradyne and others joined as new investors, and total funding passed USD 100 million. The company said the money will go to expanding production capacity, accelerating the product roadmap, and growing its engineering, regulatory and sales organizations.
People they will look for
- Robotics and automation engineer (mechanical, electrical, software) — readying the multi-arm robotic cluster for commercial-scale production and accelerating the product roadmap
- GMP quality and regulatory (RA/QA) specialist — regulatory compliance and quality systems for clusters operated directly by pharmaceutical companies
- Bioprocess (cell therapy CMC) engineer — converting industry-standard production equipment to robotic automation and transferring customer processes
For hiring managers
The company's sites are in San Francisco, USA, and Turin, Italy, so Korean talent would apply for global roles based overseas. In Korea, large biopharmaceutical contract manufacturers (CDMOs), cell and gene therapy companies and bio equipment makers are looking for the same GMP automation and quality talent, so now, as the company expands its organization with the Series B, is a good time to make contact.
For job seekers
GMP production experience in cell and gene therapy combined with a background working with robotic and automation equipment is what this company values most right now. It is worth confirming in advance that the work location is the USA or Italy.
An analysis written from public sources. Sources: Multiply Labs press release 2026-10-06 (Series B, investors, 74%, 100 times, use of funds), BioSpace 2026-10-07 (founded 2016, YC, San Francisco, pharmaceutical ownership model), Business Wire via Yahoo Finance 2026-01-27 (AstraZeneca collaboration), Multiply Labs press release 2026-05-27 (Multiply Labs Italia, Enrico Racca, customers), Multiply Labs news page (NVIDIA collaboration 2026-01-12).
Open jobs
Banseog checks official company careers pages every day. A job is marked closed only when the official page returns a removal (404 or 410).